Risperdal Attorneys at Bernstein Liebhard LLP Comment on Growth of Risperdal Mass Tort Litigation Underway in Pennsylvania

Share Article

The Firm is representing numerous plaintiffs who have filed Risperdal lawsuits in Pennsylvania that allege the antipsychotic medication caused gynecomastia, or male breast development.

Free Case Review
Our Firm is representing numerous plaintiffs in the Risperdal litigation underway in Pennsylvania.

Risperdal lawsuits (http://www.risperdallawsuit2014.com/) helped fuel a 150% jump in the number of cases filed last year in Pennsylvania’s Philadelphia Court of Common Pleas, where the state’s Complex Litigation Center is located. According to statistics compiled by The Pennsylvania Record, 2,095 new claims were filed in the various mass tort proceedings underway in Philadelphia, including 987 Risperdal cases.* Court documents indicate that as of March 6th, 1,287 lawsuits were pending in Pennsylvania’s Risperdal litigation, all of which were brought on behalf of individuals who allegedly developed gynecomastia (male breast growth) and other serious complications related to its use. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm is representing numerous plaintiffs in the Risperdal litigation underway in Pennsylvania, and we continue to actively file cases in the proceeding. As we regularly hear from individuals who allegedly developed gynecomastia due to Risperdal, we are not surprised that these claims made up such a large portion of the mass tort filings in Philadelphia last year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide legal consultations to men and boys who allegedly developed gynecomastia, due to their use of Risperdal.

Risperdal Allegations
According to court documents, all of the Risperdal lawsuits currently pending in Pennsylvania accuse Johnson & Johnson and its Janssen Pharmaceuticals division of concealing the risks associated with the drug, and of failing to warn doctors and patients about the complications that could occur with its use. The lawsuits further claim that the companies improperly marketed Risperdal for off-label uses, including pediatric indications prior to their 2006 regulatory approval. Specifically, Risperdal claims involving gynecomastia allege that the company concealed data suggesting the drug could cause a patient to experience elevate levels of a hormone called prolactin, which is related to female breast growth and the development of gynecomastia in men and boys.

Court records indicate that the Pennsylvania litigation's second bellwether trial involving Risperdal and gynecomastia is currently underway. The case now at trial was filed on behalf of a plaintiff who was prescribed Risperdal as a child to treat oppositional defiant disorder before the medication was approved for any pediatric uses. (Case No. 130301803)

According to court documents, the proceeding’s first bellwether trial of a gynecomastia lawsuit concluded on February 24th, with the jury awarding $2.5 million to a man who was prescribed the medication off-label as a boy to treat autism. According to the complaint, the plaintiff developed size 44 DD breasts as a result of his treatment with Risperdal. (Case No. A-196444)

Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.

*pennrecord.com/news/15821-risperdal-pelvic-mesh-suits-cause-spike-in-filings-at-philadelphias-mass-torts-program, Pennsylvania Record, February 19, 2015

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website